GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (STU:MLZ) » Definitions » Debt-to-Asset

MediPharm Labs (STU:MLZ) Debt-to-Asset : 0.04 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is MediPharm Labs Debt-to-Asset?

MediPharm Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.40 Mil. MediPharm Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.04 Mil. MediPharm Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €41.63 Mil. MediPharm Labs's debt to asset for the quarter that ended in Mar. 2024 was 0.03.


MediPharm Labs Debt-to-Asset Historical Data

The historical data trend for MediPharm Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Debt-to-Asset Chart

MediPharm Labs Annual Data
Trend Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial 0.06 0.16 - 0.01 0.04

MediPharm Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 0.04 0.04 0.04

Competitive Comparison of MediPharm Labs's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediPharm Labs's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Debt-to-Asset falls into.



MediPharm Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

MediPharm Labs's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

MediPharm Labs's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediPharm Labs  (STU:MLZ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


MediPharm Labs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


MediPharm Labs (STU:MLZ) Business Description

Traded in Other Exchanges
Address
151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis extracts and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

MediPharm Labs (STU:MLZ) Headlines

No Headlines